TNF and cervical cancer: Table 3). Comparing Groups 1 and 3, we found there was no significant relationship between TNF rs1800629 polymorphism and cervical cancer (AA vs. GG: OR  = 0.993, 95% CI: 0.376–2.618, P = 0.988. Table 4). Comparing Groups 1 and 2, we found no significant association between TNF rs1800629 polymorphism and cervical cancer with HPV infection (AA vs. GG: OR  = 0.663, 95% CI: 0.250–1.758, P = 0.409. Table 5). No associations were found in combined genotypes (AA vs. GG+GA or GG vs. GA+AA) with cervical cancer risk (Table 3–5).